Press Releases



    • MAR 31 2015

    ONC201 Featured in Seven Abstracts at 2015 AACR Meeting

    Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for

    • MAR 31 2015

    Oncoceutics Awarded NCI Grant for Clinical Trial of ONC201 in GBM

    Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc. announced that the company was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The combined Phase I/II Fast Track grant will support a clinical trial in ONC201 in advanced brain cancer, furthering the clinical development of the company’s lead compound. ONC201